Nasdaq Bmrn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Motley Fool Wealth Management LLC trimmed its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the period. BioMarin Pharmaceutical makes up about 2.4% of Motley Fool Wealth […]

Motley Fool Wealth Management LLC reduced its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 470,289 shares of the biotechnology company’s stock after selling 18,667 shares during the quarter. […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its price objective decreased by Morgan Stanley from $115.00 to $112.00 in a research note released on Friday, Benzinga reports. Morgan Stanley currently has an overweight rating on the biotechnology company’s stock. Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed […]

Xponance Inc. cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 2.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,966 shares of the biotechnology company’s stock after selling 203 shares during the quarter. Xponance […]

BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) had its target price lowered by Citigroup from $94.00 to $91.00 in a research note published on Thursday morning, Benzinga reports. Citigroup currently has a neutral rating on the biotechnology company’s stock. Several other research analysts have also issued reports on BMRN. Royal Bank of Canada restated a sector […]